ABSTRACT: Cancer heterogeneity provides a formidable obstacle to optimizing clinical protocols to achieve durable clinical responses [...].

SUBMITTER: Baxevanis CN

PROVIDER: S-EPMC10046681 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature